Esprit™ BTK
Everolimus Eluting Resorbable Scaffold System

Proven With 2-Year RCT Data

SUPERIOR EFFICACY, SUSTAINED BENEFITS THROUGH 2 YEARS[1†]

The LIFE-BTK Study, published in the *New England Journal of Medicine*, is the first successful RCT to demonstrate superiority of an interventional device over standard of care for treatment of BTK disease in CLTI patients. The 2-year data demonstrated sustained efficacy and safety.

48% fewer patients require reintervention at 2 years[1*]

Clinically driven target lesion revascularization at 2 years



Superior results, sustained benefits[1†]

Esprit™ BTK System had 30.8% improvement (74.5% vs. 43.7%) in primary efficacy (limb salvage and primary patency) at 1 year[2] with sustained benefits through 2 years.[1]



References on page 3.

Information contained herein for DISTRIBUTION outside of the U.S. ONLY. Check the regulatory status of the device in your country or region prior to use.

Abbott

The Esprit™ BTK System is the only BTK device that does it all for CLTI:

Delivers drug, provides support, and leaves nothing behind.[3-5]



SCAFFOLD
Supports treated artery to address vessel recoil and dissection

RESORBABLE
100% resorbable

EVEROLIMUS
Sustained everolimus elution to inhibit restenosis and maximize patency

LIFE-BTK Trial Objective

To evaluate the safety and efficacy of the Abbott Esprit™ BTK Everolimus Eluting Resorbable Scaffold System, compared to Balloon Angioplasty, for the treatment of infrapopliteal artery disease in patients with CLTI.

Global prospective, randomized, multicenter, single-blind trial.

- 261 patients
- 2:1 Esprit™ BTK System vs. Balloon Angioplasty
- 5-year follow up
- Esprit™ BTK arm had a high clinical follow up at 2 years of 87.9%



Patient Demographics and History Risk Factors

All patients in the LIFE-BTK trial presented with CLTI with either ischemic rest pain (Rutherford-Becker class 4) or minor tissue loss (Rutherford-Becker class 5) along with multiple risk factors.

	Esprit™ BTK System	Balloon Angioplasty
Hypertension	94.2%	90.9%
Hyperlipidemia	80.9%	81.8%
Tobacco Use	52.6%	53.4%
Diabetes	71.1%	69.3%
Rutherford Becker 4	52.0%	51.1%
Rutherford Becker 5	48.0%	48.9%
Prior PAD	82.7%	77.3%

Scan QR code for more information on the Esprit™ BTK System

References on page 3.

† Superiority analysis was performed at 1 year.
* Reintervention defined as CD-TLR.

1. Brian G. DeRubertis et al., Two-Year Outcomes of the LIFE-BTK Randomized Controlled Trial Evaluating the Esprit™ BTK Drug-eluting Resorbable Scaffold for Treatment of Infrapopliteal Lesions, VIVA 2024.
2. Varcoe, RL., et al. Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease. *N Eng J Med* 2024;390:9-19.
3. Esprit™ BTK Everolimus Eluting Resorbable Scaffold System Instructions for Use (IFU). Refer to IFU for additional information.
4. Data on file at Abbott.
5. Excluding platinum markers.

CAUTION: This product is intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or at manuals.eifu.abbott for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events. This material is intended for use with healthcare professionals only.

Information contained herein for DISTRIBUTION outside of the U.S. ONLY. Check the regulatory status of the device in areas where CE marking is not the regulation in force.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs. Photos on file at Abbott.

Abbott International BV
Park Lane, Culliganlaan 2B, 1831 Diegem, Belgium, Tel: 32.2.714.14.11

www.cardiovascular.abbott